Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

IGMS | IGM Biosciences Inc

IndexRUT P/E- EPS (ttm)-5.27 Insider Own60.71% Shs Outstand29.39M Perf Week3.04%
Market Cap393.44M Forward P/E- EPS next Y-4.50 Insider Trans0.36% Shs Float20.72M Perf Month-1.32%
Income-234.34M PEG- EPS next Q-1.22 Inst Own42.12% Short Float / Ratio27.24% / 21.21 Perf Quarter-17.29%
Sales1.67M P/S235.59 EPS this Y3.62% Inst Trans-0.69% Short Interest5.64M Perf Half Y-51.50%
Book/sh4.90 P/B1.52 EPS next Y12.29% ROA-44.10% Target Price22.09 Perf Year-62.25%
Cash/sh7.35 P/C1.02 EPS next 5Y- ROE-73.92% 52W Range6.45 - 28.20 Perf YTD-56.14%
Dividend- P/FCF- EPS past 5Y-71.19% ROI-79.94% 52W High-73.55% Beta-0.24
Dividend %- Quick Ratio9.07 Sales past 5Y0.00% Gross Margin-638.14% 52W Low15.66% ATR0.53
Employees258 Current Ratio9.07 Sales Q/Q22.40% Oper. Margin-14845.07% RSI (14)48.36 Volatility8.77% 7.16%
OptionableYes Debt/Eq0.16 EPS Q/Q-7.01% Profit Margin-14007.47% Rel Volume0.47 Prev Close7.28
ShortableYes LT Debt/Eq0.13 EarningsAug 03 AMC Payout- Avg Volume266.11K Price7.46
Recom1.64 SMA203.10% SMA50-10.34% SMA200-46.78% Volume68,332 Change2.47%
Date Action Analyst Rating Change Price Target Change
Nov-09-22Resumed Jefferies Buy $61 → $55
Oct-17-22Initiated JP Morgan Neutral $27
Aug-29-22Initiated BofA Securities Buy $34
Dec-13-21Downgrade RBC Capital Mkts Outperform → Sector Perform $51
Nov-05-21Upgrade Wedbush Neutral → Outperform
Aug-26-21Initiated Morgan Stanley Overweight $100
Jan-29-21Initiated RBC Capital Mkts Outperform $121
Jan-19-21Reiterated H.C. Wainwright Buy $88 → $114
Dec-22-20Downgrade Wedbush Outperform → Neutral
Jul-17-20Initiated Robert W. Baird Outperform $90
Oct-14-19Initiated Guggenheim Buy $30
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
06:46AM Loading…
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
11:58AM Loading…
May-25-23 11:58AM
May-12-23 10:15AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
07:00AM Loading…
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
Apr-05-22 04:56PM
Mar-30-22 03:06PM
Mar-29-22 11:41AM
Feb-09-22 03:34PM
Feb-03-22 04:05PM
Jan-10-22 10:00AM
Jan-05-22 07:00AM
Dec-13-21 09:43AM
Dec-11-21 01:31PM
Dec-09-21 07:36AM
Dec-08-21 07:00AM
Dec-06-21 04:05PM
Nov-10-21 04:05PM
Nov-08-21 07:00AM
Nov-04-21 11:25AM
Oct-11-21 04:05PM
Oct-06-21 11:44AM
Sep-23-21 04:05PM
Sep-10-21 09:01AM
Sep-07-21 07:00AM
Aug-09-21 04:06PM
Jul-29-21 05:31PM
Jul-26-21 08:17PM
Jun-12-21 05:05AM
Jun-03-21 07:01AM
May-26-21 07:00AM
May-12-21 07:00AM
May-03-21 08:02AM
Apr-27-21 07:00AM
Apr-12-21 07:00AM
Mar-30-21 04:17PM
Mar-24-21 07:00AM
Mar-15-21 07:00AM
Mar-14-21 05:52AM
Mar-08-21 09:51AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gauthier GeorgeChief Commercial OfficerJul 03Sale9.429368,81840,017Jul 05 09:08 PM
Topsoe Jakob HaldorDirectorJun 30Buy9.253,50032,37581,644Jul 03 06:46 PM
Topsoe Christina TengDirectorJun 30Buy9.323,00027,9579,800Jul 05 09:07 PM
Redmile Group, LLCDirectorJun 29Buy9.4280,423757,5852,974,186Jul 03 09:45 PM
Topsoe Jakob HaldorDirectorJun 29Buy9.103,50031,84678,144Jul 03 06:46 PM
Redmile Group, LLCDirectorJun 29Sale9.4280,423757,5852,893,763Jul 03 09:45 PM
BEHRENS M KATHLEENDirectorJun 26Buy8.00112,500900,000330,700Jun 28 07:34 PM
Gauthier GeorgeChief Commercial OfficerMay 23Sale12.311,25915,49740,953May 25 07:20 PM
Decker Lisa LynnChief Business OfficerMay 23Sale12.311,25915,49741,181May 25 07:20 PM
Tahir MisbahChief Financial OfficerMay 23Sale12.311,25915,49750,711May 25 07:23 PM
Takimoto Chris HChief Medical OfficerMay 23Sale12.311,25915,49754,742May 25 07:24 PM
Schwarzer FredCEO and PresidentMay 23Sale12.311,25915,497121,761May 25 07:22 PM
Keyt BruceChief Scientific OfficerMay 23Sale12.3198212,088138,058May 25 07:21 PM
Gauthier GeorgeChief Commercial OfficerApr 05Sale12.6093511,78133,878Apr 06 09:39 PM
Takimoto Chris HChief Medical OfficerMar 14Sale18.731,76833,11828,789Mar 16 06:31 PM
Tahir MisbahChief Financial OfficerMar 14Sale18.731,76833,11825,322Mar 16 06:30 PM
Keyt BruceChief Scientific OfficerMar 14Sale18.731,29324,22090,704Mar 16 06:30 PM
Gauthier GeorgeChief Commercial OfficerMar 14Sale18.731,06119,87518,563Mar 16 06:28 PM
Decker Lisa LynnChief Business OfficerMar 14Sale18.731,06119,87516,732Mar 16 06:27 PM
Keyt BruceChief Scientific OfficerJan 05Option Exercise0.9333,75631,39391,997Jan 09 06:16 PM
Tahir MisbahChief Financial OfficerDec 19Sale20.003,80176,02027,090Dec 20 08:09 PM
Schwarzer FredCEO and PresidentDec 16Sale18.9812,369234,80520,360Dec 20 08:08 PM
Takimoto Chris HChief Medical OfficerDec 16Sale18.985,430103,08030,557Dec 20 08:12 PM
Keyt BruceChief Scientific OfficerDec 16Sale18.985,371101,96058,241Dec 20 08:07 PM
Gauthier GeorgeChief Commercial OfficerDec 16Sale18.984,35482,65419,624Dec 20 08:06 PM
Decker Lisa LynnChief Business OfficerDec 16Sale18.982,48447,15417,793Dec 20 08:05 PM
Tahir MisbahChief Financial OfficerDec 16Sale18.982,28343,33930,891Dec 20 08:09 PM
Keyt BruceChief Scientific OfficerDec 14Option Exercise0.9325,00023,25063,612Dec 16 07:40 PM
Gauthier GeorgeChief Commercial OfficerNov 23Sale21.571,25827,13623,978Nov 28 08:28 PM
Decker Lisa LynnChief Business OfficerNov 23Sale21.571,25827,13620,277Nov 28 08:27 PM
Schwarzer FredCEO and PresidentNov 23Sale21.571,25827,13632,729Nov 28 08:30 PM
Takimoto Chris HChief Medical OfficerNov 23Sale21.5787718,91835,987Nov 28 08:31 PM
Tahir MisbahChief Financial OfficerNov 23Sale21.5787718,91833,174Nov 28 08:31 PM
Keyt BruceChief Scientific OfficerNov 23Sale21.5787718,91838,612Nov 28 08:29 PM
BEHRENS M KATHLEENDirectorNov 08Buy17.1460,0001,028,550218,200Nov 10 05:10 PM
Keyt BruceChief Scientific OfficerOct 04Option Exercise0.9325,00023,25064,489Oct 06 07:16 PM
Keyt BruceChief Scientific OfficerOct 04Sale22.8425,000570,98039,489Oct 06 07:16 PM
LOBERG MICHAEL DDirectorSep 29Buy19.625,821114,21335,305Oct 03 08:11 PM
LOBERG MICHAEL DDirectorSep 28Buy20.976,172129,40329,484Sep 29 06:05 PM
LOBERG MICHAEL DDirectorSep 27Buy19.9950710,13723,312Sep 29 06:05 PM